Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response
- 1 June 2009
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 27 (4) , 341-354
- https://doi.org/10.2165/00019053-200927040-00006
Abstract
Background:Recently developed German guidelines for antiviral treatment in patients with chronic hepatitis C recommend basing drug dosage, intended treatment duration and early stopping rules on the...Keywords
This publication has 56 references indexed in Scilit:
- Standardtherapie der akuten und chronischen Hepatitis CZeitschrift für Gastroenterologie, 2004
- Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis CPharmacoEconomics, 2004
- When should decision-analytic modeling be used in the economic evaluation of health care?The European Journal of Health Economics, 2003
- National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002Hepatology, 2002
- Cost-effectiveness of combination therapy for naive patients with chronic hepatitis CNoteJournal of Hepatology, 2000
- Making cost assessments based on RCTs more useful to decision-makersHealth Policy, 1996
- Sclerotherapy for Male Alcoholic Cirrhotic Patients Who Have Bled From Esophageal Varices: Results of A Randomized, Multicenter Clinical TrialHepatology, 1994
- Liver transplantation for hepatitis C virus-related cirrhosisHepatology, 1994
- Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitisJournal of Hepatology, 1992
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981